BCM
KYMR icon

Bayesian Capital Management’s Kymera Therapeutics KYMR Stock Holding History

Bayesian Capital Management’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-9,400
Closed -$445K – 852
2024
Q3 		$445K Buy
+9,400
New +$415K 0.05% 398
2024
Q2 		– Sell
-14,150
Closed -$569K – 930
2024
Q1 		$569K Buy
+14,150
New +$506K 0.05% 412
2022
Q2 		– Sell
-4,780
Closed -$202K – 945
2022
Q1 		$202K Buy
+4,780
New +$202K 0.03% 653

Other funds holding KYMR

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Bayesian Capital Management's KYMR Position: Q4 2024 in Review

Bayesian Capital Management sold out of Kymera Therapeutics (KYMR) in Q4 2024, closing a stake of 9,400 shares — an estimated $445K sold.

Bayesian Capital Management first reported a position in KYMR in Q1 2022 and held it in 3 quarters. The position peaked at $569K in Q1 2024. 180 funds tracked by Wall St. Rank hold KYMR as of Q4 2024.

  • Bayesian Capital Management reported no remaining Kymera Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Bayesian Capital Management sold 9,400 Kymera Therapeutics shares in Q4 2024, an estimated $445K.
  • Bayesian Capital Management first reported a position in Kymera Therapeutics in Q1 2022 and held it in 3 quarters.
  • Bayesian Capital Management's Kymera Therapeutics position peaked at $569K in Q1 2024.
  • 180 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q4 2024.

Based on Bayesian Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.